Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Improved curve fits to summary survival data: application to economic evaluation of health technologies

4 references·16 citing·36 second hop

FromToDepth

this work references cited by second hop

References

2007Practical methods for incorporating summary time-to-event data into meta-analysis6,205 cited
1998Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints4,809 cited
2006Decision Modelling For Health Economic Evaluation3,144 cited
2002Aggregate data meta‐analysis with time‐to‐event outcomes551 cited

Cited by

2020Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?152 cited
2019First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma150 cited
2013Overview of Parametric Survival Analysis for Health-Economic Applications133 cited
2015Simulation and Matching-Based Approaches for Indirect Comparison of Treatments110 cited
2017Cost-Effectiveness of Immune Checkpoint Inhibition inBRAFWild-Type Advanced Melanoma108 cited
2015Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer94 cited
2021Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma80 cited
2019Estimating hazard ratios from published Kaplan‐Meier survival curves: A methods validation study79 cited
2025Practical methods for incorporating summary time-to-event data into meta-analysis: updated guidance63 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

2019Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater60 cited

2017Economic evaluation of nivolumab as a second‐line treatment for advanced renal cell carcinoma from US and C hinese perspectives55 cited

2021Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China55 cited

2020Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC54 cited

2018A simple method for combining binomial counts or proportions with hazard ratios for evidence synthesis of time‐to‐event data36 cited

2022A Method for Reconstructing Individual Patient Data From Kaplan-Meier Survival Curves That Incorporate Marked Censoring Times32 cited

2020A non-linear optimisation method to extract summary statistics from Kaplan-Meier survival plots using the published P value13 cited